相关实验视频

Updated: May 5, 2026

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

卡姆雷利祖马布加上凝胺和氧沙,用于复发性或耐火性古典霍奇金淋巴瘤:II期临床试验

Yanfei Liu¹, Lingyan Ping¹, Yuqin Song¹

¹Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Fucheng Road 52, Haidian Region, Beijing, 100142, China.

|March 8, 2024

概括

卡姆雷利祖马布 (Camrelizumab) 加上凝胺和氧沙 (GEMOX) 显示出作为耐火性或复发性古典霍奇金淋巴瘤 (cHL) 的有效救援疗法的承诺. 这种组合治疗促进了自身干细胞移植,并导致大多数患者的持续缓解.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床试验临床试验

背景情况:

经典霍奇金淋巴瘤 (cHL) 通常是可以治愈的,但对于耐药或复发 (R/R) 疾病患者来说,新型疗法是必不可少的.
现有的治疗方法可能对所有R/RcHL患者都不有效,因此需要探索新的治疗策略.

研究的目的:

评估卡姆雷利祖马布与凝胺和氧沙 (GEMOX) 结合的疗效和安全性,作为R/RcHL患者的救援疗法.
评估在自身干细胞移植 (ASCT) 之前的完全响应 (CR) 率和随后的结果.

主要方法:

一项II期临床试验,涉及可移植的R/RcHL患者.
患者接受了卡姆雷利祖马布,格姆西塔和氧沙 (GEMOX) 的循环治疗.
响应评估指导了进一步的治疗,响应者继续进行ASCT.

主要成果:

在可评估患者中观察到的客观应答率为94.9%,CR率为69.2%.
69%的患者进行了ASCT,有些人在移植后获得了CR.
12个月无进展生存率为96.6%,总生存率为100%,有可管理的毒性.

结论:

卡姆雷利祖马布加GEMOX是一种有效的R/R cHL的救援方案.
组合疗法耐受性良好,可实现ASCT,导致持续缓解.
这种方案为需要进一步治疗的R/RcHL患者提供了一个有希望的选择.

关键词:

卡姆雷利兹马巴姆 (Camrelizumab) 是一个杰姆西塔宾 (Gemcitabine) 是一种药物.霍奇金病是一种霍奇金病.氧化酸是一种氧化酸.

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...